Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seoul Seeks To Expand Biomedical Fund With MOUs Signed With U.S. States Massachusetts And Maryland

This article was originally published in PharmAsia News

Executive Summary

SEOUL - The Seoul Metropolitan Government is pushing to expand its KRW 100 billion ($92.2 million) biomedical fund, established last year by the Boston venture capital firm Oxford Bioscience Partners and Korea's Hanwha Venture Capital to boost Korea's life sciences industries

You may also be interested in...



Korea's Medical Tourism Push Can Benefit Korean And Global Pharma - Medical Korea 2011

SEOUL - South Korea's bid to top Thailand, India and Singapore as an Asian hub for healthcare services, particularly medical tourism, should be beneficial to both Korean and global pharmas, Seoul officials said

Korea Expects MOU with Cigna To Attract More Medical Tourism Patients, Possibly From China - Medical Korea 2011 Conference

SEOUL - South Korea expects to sign an MOU with Cigna International next month as part of its efforts to establish Korea as an attractive medical tourism destination, Kim Bup-wan, president of the Korea Health Industry Development Institute told local reporters

Korea Signs Healthcare MOU With UAE; Seeks Out More Global Partners To Draw Medical Tourism To Korea

SEOUL - South Korea's Ministry of Health and Welfare has signed a memorandum of understanding with the United Arab Emirates to bring the latter's patients into Korea for medical treatments not available in UAE

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC077795

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel